FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229083613> ?p ?o ?g. }

• W4229083613 abstract "Over the past decade, a new class of drugs called CFTR (cystic fibrosis transmembrane conductance regulator) modulators have shown to be able to improve clinical outcomes in patient with Cystic Fibrosis. In this analysis, we have extensively reviewed the regulatory pathways and decisions adopted by FDA and EMA to speed up the development, the review and the approval of these drugs, with the aim of identifying possible clinical and public health implications associated with differences.CFTR modulators have been developed towards addressing three main genetic domains: (1) F508del homozygous (F508del/F508del), (2) F508del heterozygous, and (3) genotypes not carrying F508del mutation; and expanded from adult to paediatric population. Programs to expedite the reviewing and licensing of CFTR modulators were extensively adopted by FDA and EMA. All CFTR modulators have been licensed in the US as orphan drugs, but in the EU the orphan status for LUM/IVA was not confirmed at the time of marketing authorization as results from the pivotal trial were not considered clinically significant. While FDA and EMA approved CFTR modulators on the basis of results from phase III double-blind RCTs, main differences were found on the extension of indications: FDA accepted non-clinical evidence considering a recovery of the CFTR function ≥ 10% based on chloride transport, a reliable indicator to correlate with improvement in clinical outcomes. By contrast, EMA did not deem preclinical data sufficient to expand the label of CFTR modulators without confirmatory clinical data.Regulators played an important role in fostering the development and approval of CFTR modulators. However, differences were found between FDA and EMA in the way of reviewing and licensing CFTR modulators, which extended beyond semantics affecting patients' eligibility and access: FDA's approach was more mechanistic/biology-driven while the EMA's one was more oriented by clinical evidence. This might refer to the connection between the EMA and the Member States, which tends to base decisions on pricing and reimbursement on clinical data rather than pre-clinical ones. Here we have proposed a two-step personalized-based model to merge the ethical commitment of ensuring larger access to all potential eligible patients (including those harboring very rare mutations) with the one of ensuring access to clinically assessed and effective medicines through Real World Data." @default.
• W4229083613 created "2022-05-08" @default.
• W4229083613 creator A5002688058 @default.
• W4229083613 creator A5004497604 @default.
• W4229083613 creator A5014306442 @default.
• W4229083613 creator A5035747289 @default.
• W4229083613 creator A5037721874 @default.
• W4229083613 date "2022-05-07" @default.
• W4229083613 modified "2023-10-16" @default.
• W4229083613 title "The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis" @default.
• W4229083613 cites W1589654967 @default.
• W4229083613 cites W1989308735 @default.
• W4229083613 cites W2028171116 @default.
• W4229083613 cites W2031633609 @default.
• W4229083613 cites W2035131077 @default.
• W4229083613 cites W2049914201 @default.
• W4229083613 cites W2078078890 @default.
• W4229083613 cites W2095687634 @default.
• W4229083613 cites W2116707205 @default.
• W4229083613 cites W2125391335 @default.
• W4229083613 cites W2133435216 @default.
• W4229083613 cites W2134224630 @default.
• W4229083613 cites W2140868856 @default.
• W4229083613 cites W2149372853 @default.
• W4229083613 cites W2153907656 @default.
• W4229083613 cites W2254054106 @default.
• W4229083613 cites W2301131921 @default.
• W4229083613 cites W2316431812 @default.
• W4229083613 cites W2468020936 @default.
• W4229083613 cites W2611293674 @default.
• W4229083613 cites W2624387478 @default.
• W4229083613 cites W2751925857 @default.
• W4229083613 cites W2763812341 @default.
• W4229083613 cites W2765825922 @default.
• W4229083613 cites W2798259805 @default.
• W4229083613 cites W2799520701 @default.
• W4229083613 cites W2805157317 @default.
• W4229083613 cites W2884486468 @default.
• W4229083613 cites W2886660386 @default.
• W4229083613 cites W2888034354 @default.
• W4229083613 cites W2897626245 @default.
• W4229083613 cites W2911232211 @default.
• W4229083613 cites W2911418673 @default.
• W4229083613 cites W2956193224 @default.
• W4229083613 cites W2982296199 @default.
• W4229083613 cites W2985405196 @default.
• W4229083613 cites W2995324985 @default.
• W4229083613 cites W3008025512 @default.
• W4229083613 cites W3014378002 @default.
• W4229083613 cites W3019764296 @default.
• W4229083613 cites W3035224642 @default.
• W4229083613 cites W3087664250 @default.
• W4229083613 cites W3091872874 @default.
• W4229083613 cites W3137031156 @default.
• W4229083613 cites W3195812235 @default.
• W4229083613 cites W3214212058 @default.
• W4229083613 cites W4205612199 @default.
• W4229083613 cites W4206217612 @default.
• W4229083613 cites W4214721068 @default.
• W4229083613 cites W4221014305 @default.
• W4229083613 cites W4232035537 @default.
• W4229083613 cites W4241884576 @default.
• W4229083613 doi "https://doi.org/10.1186/s13023-022-02350-5" @default.
• W4229083613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35525974" @default.
• W4229083613 hasPublicationYear "2022" @default.
• W4229083613 type Work @default.
• W4229083613 citedByCount "14" @default.
• W4229083613 countsByYear W42290836132022 @default.
• W4229083613 countsByYear W42290836132023 @default.
• W4229083613 crossrefType "journal-article" @default.
• W4229083613 hasAuthorship W4229083613A5002688058 @default.
• W4229083613 hasAuthorship W4229083613A5004497604 @default.
• W4229083613 hasAuthorship W4229083613A5014306442 @default.
• W4229083613 hasAuthorship W4229083613A5035747289 @default.
• W4229083613 hasAuthorship W4229083613A5037721874 @default.
• W4229083613 hasBestOaLocation W42290836131 @default.
• W4229083613 hasConcept C108759981 @default.
• W4229083613 hasConcept C126322002 @default.
• W4229083613 hasConcept C2776502428 @default.
• W4229083613 hasConcept C2776938444 @default.
• W4229083613 hasConcept C2777589142 @default.
• W4229083613 hasConcept C2778428886 @default.
• W4229083613 hasConcept C2908647359 @default.
• W4229083613 hasConcept C38652104 @default.
• W4229083613 hasConcept C41008148 @default.
• W4229083613 hasConcept C502991105 @default.
• W4229083613 hasConcept C535046627 @default.
• W4229083613 hasConcept C60644358 @default.
• W4229083613 hasConcept C71924100 @default.
• W4229083613 hasConcept C75480439 @default.
• W4229083613 hasConcept C86803240 @default.
• W4229083613 hasConcept C98274493 @default.
• W4229083613 hasConcept C99454951 @default.
• W4229083613 hasConceptScore W4229083613C108759981 @default.
• W4229083613 hasConceptScore W4229083613C126322002 @default.
• W4229083613 hasConceptScore W4229083613C2776502428 @default.
• W4229083613 hasConceptScore W4229083613C2776938444 @default.
• W4229083613 hasConceptScore W4229083613C2777589142 @default.
• W4229083613 hasConceptScore W4229083613C2778428886 @default.
• W4229083613 hasConceptScore W4229083613C2908647359 @default.

• next